OBJECTIVES To assess the effect of two doses, i.e., 10 mg and 25 mg of empafliflozin, on the lipid profile of patients with type 2 diabetes mellitus (T2DM) with suboptimal glycemic control on maximal doses of metformin and sitagliptin. METHODOLOGY The study design was a random ized, open-label clinical trial. Fifty-nine adult patients of T2DM who were already on 2000 mg of Metformin and 100 mg of Sitagliptin and were having suboptimal glycaemic control (HBA1C > 7% <12%) were randomly allocated in 1:1 ratio to two groups, one group receiving 10 mg (Group A) and the other group receiving 25 mg of Empagli?ozin (Group B) as an additional treatment. Fasting lipid pro?les, including total cholesterol (TC), low-density cholesterol (LDL-C), high-density cholesterol (HDL-C) and triglyce rides (TG), were taken before and 12 weeks after the addition of empagli?ozin in both the groups. RESULTS Total patients in group A were 31, and their mean age was 51.48±4.29 years. In group B, there were 28 patients, whose mean age was 52.39 ± 5.20 years. There was an increase in TC, LDL-C and HDL-C and a reduction of TG in both the groups after treatment with empagli?ozin, but it was not statistically signi?cant (p >0.05). CONCLUSION Both doses of Empagliflozin (10 and 25 mg) modestly elevates total cholesterol, LDL -C and HDL-C and modestly reduce triglyceride levels in T2DM patients, but the change is not statistically significant.